Table of Contents
ISRN Obstetrics and Gynecology
Volume 2011 (2011), Article ID 292951, 9 pages
http://dx.doi.org/10.5402/2011/292951
Clinical Study

Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial

1Gyneco-obstetric Hospital Ramon Gonzalez Coro, Havana 10400, Cuba
2Clinical Trials Division, Center for Biological Research, Havana 6996, Cuba
3Gyneco-obstetric Hospital Mariana Grajales, Santa Clara 50100, Cuba
4General Hospital Carlos Manuel de Céspedes, Bayamo 85100, Cuba
5Department of Cancer, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Havana 10600, Cuba
6Department of Genomics, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba

Received 5 January 2011; Accepted 26 January 2011

Academic Editors: R. M. Austin and K. Chan

Copyright © 2011 Ana M. Solares et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Ana M. Solares, Idania Baladron, Thelvia Ramos, et al., “Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial,” ISRN Obstetrics and Gynecology, vol. 2011, Article ID 292951, 9 pages, 2011. doi:10.5402/2011/292951